We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

127 hedge funds and large institutions have $469M invested in Intra-Cellular Therapies Inc. in 2019 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 52 increasing their positions, 28 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

873% more call options, than puts

Call options by funds: $42.6M | Put options by funds: $4.38M

86% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 28

12% more capital invested

Capital invested by funds: $418M → $469M (+$51.5M)

0% more funds holding

Funds holding: 127 → 127 (0)

0% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 13

Holders
127
Holders Change
–
Holders Change %
0%
% of All Funds
2.75%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
52
Reduced
28
Closed
13
Calls
$42.6M
Puts
$4.38M
Net Calls
+$38.2M
Net Calls Change
+$666K

Top Buyers

Rank Fund Capital Flow
1
TA
Teachers Advisors
New York
+$4.89M
2
WA
Wasatch Advisors
Utah
+$4.82M
3
RPAM
Rhenman & Partners Asset Management
Sweden
+$3.7M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.61M
5
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
+$2.52M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$12.2M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.84M
3
FCM
Farallon Capital Management
California
-$2.85M
4
Millennium Management
Millennium Management
New York
-$2.72M
5
Bank of America
Bank of America
North Carolina
-$2.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
Man Group
26
Man Group
United Kingdom
$2.96M +$552K +43,200 +22%
JP Morgan Chase
27
JP Morgan Chase
New York
$2.65M -$407K -31,824 -13%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$2.62M +$63K +4,931 +2%
DekaBank Deutsche Girozentrale
29
DekaBank Deutsche Girozentrale
Germany
$1.95M +$118K +9,200 +12%
CWG
30
C WorldWide Group
Denmark
$1.79M – – –
PAMU
31
Pictet Asset Management (UK)
United Kingdom
$1.71M +$558K +43,700 +45%
CCP
32
Clough Capital Partners
Massachusetts
$1.62M -$15.3K -1,200 -0.9%
Deutsche Bank
33
Deutsche Bank
Germany
$1.6M -$1.28M -100,319 -43%
Axa
34
Axa
France
$1.6M +$1.68M +131,611 New
Two Sigma Advisers
35
Two Sigma Advisers
New York
$1.53M +$1.25M +97,600 +345%
Bank of America
36
Bank of America
North Carolina
$1.46M -$2.04M -159,435 -57%
California Public Employees Retirement System
37
California Public Employees Retirement System
California
$1.35M +$702K +54,900 +98%
TCM
38
Tekla Capital Management
Massachusetts
$1.34M – – –
Goldman Sachs
39
Goldman Sachs
New York
$1.34M +$305K +23,859 +28%
Jacobs Levy Equity Management
40
Jacobs Levy Equity Management
New Jersey
$1.33M +$480K +37,570 +52%
TCIM
41
TIAA CREF Investment Management
New York
$1.24M +$51K +3,988 +4%
PVI
42
Pura Vida Investments
New York
$1.22M +$1.28M +100,000 New
Parallax Volatility Advisers
43
Parallax Volatility Advisers
California
$1.17M +$1.23M +96,413 New
Citadel Advisors
44
Citadel Advisors
Florida
$1.13M -$12.2M -955,461 -91%
Renaissance Technologies
45
Renaissance Technologies
New York
$1.02M -$714K -55,900 -40%
CM
46
Caption Management
Oklahoma
$975K +$1.02M +80,000 New
Swiss National Bank
47
Swiss National Bank
Switzerland
$972K +$30.7K +2,400 +3%
Ohio Public Employees Retirement System (OPERS)
48
Ohio Public Employees Retirement System (OPERS)
Ohio
$943K +$92K +7,200 +10%
Macquarie Group
49
Macquarie Group
Australia
$911K – – –
AllianceBernstein
50
AllianceBernstein
Tennessee
$895K – – –
1
2
3 4 5

ITCI Hedge Fund Activity: Q1 2019 in Review

127 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2019, worth a combined $469M — up 12% from $418M a quarter earlier.

Fund positioning in ITCI was balanced in Q1 2019: 13 funds opened new positions, 13 closed out, 52 added to existing stakes and 28 trimmed.

The largest buyer was Teachers Advisors, adding an estimated $4.89M. The largest seller was Citadel Advisors, cutting an estimated $12.2M.

  • 127 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2019, unchanged from Q4 2018.
  • Funds reported $469M of Intra-Cellular Therapies Inc. stock for Q1 2019, up 12% quarter-over-quarter.
  • 13 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2019 and 13 closed out, a net change of 0 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q1 2019 was Teachers Advisors, an estimated $4.89M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q1 2019 was Citadel Advisors, an estimated $12.2M sold.

Based on aggregated 13F filings for Q1 2019.